TY - JOUR
T1 - Evolution of combined impaired fasting glucose and impaired glucose tolerance in β-thalassemia major
T2 - Results in 58 patients with a mean 7.7-year follow-up
AU - De Sanctis, Vincenzo
AU - Daar, Shahina
AU - Soliman, Ashraf T.
AU - Tzoulis, Ploutarchos
AU - Yassin, Mohamed A.
AU - Kattamis, Christos
N1 - Publisher Copyright:
© 2022, Mattioli 1885. All rights reserved.
PY - 2022
Y1 - 2022
N2 - Background: Advances in β-thalassemia major (β-TM) care have transformed a disease which had previously led to an early childhood death into a chronic condition. With increased lifespan, comorbidities associated with the disease have become more common, among them glucose dysregulation (GD) which devel-ops insidiously, aggravating prognosis and patients’ quality of life. Objectives: The objectives of this study were to retrospectively review the extent to which β-TM patients, having combined impaired fasting glucose (IFG) and impaired glucose tolerance test (IGT) on oral glucose tolerance test (OGTT), progressed to diabetes and to analyze the potential determinants inducing this progression, or regression to normal glucose tolerance test (NGT). Research design and method: Data of 58 β-TM patients, followed for a mean duration of 7.7 years (range: 1-20 years) with annual or biennial OGTT, were retrieved. Insulin release and insulin sensitivity (IS) were also analyzed. Results: During the follow-up, FPG and 2-h PG levels after OGTT reverted to NGT in 13 patients (22.4%), deteriorated in 13 patients (22.4%) who developed diabetes mellitus, and did not change in the remaining 32 patients (55.2%). A significant correlation was observed between FPG and ALT level (r: 0.3158; P:0.01) and an inverse correlation was found between chronological age and serum ferritin (SF) level (r:-0.321; P:0.014). Finally, SF and ALT, both at the baseline and at the time of last observation, were independent predictors of evolution to diabetes mellitus. Conclusion: The combination IFG/IGT in β-TM patients with severe iron overload constitutes a high-risk state for developing diabetes. (www.actabiomedica.it).
AB - Background: Advances in β-thalassemia major (β-TM) care have transformed a disease which had previously led to an early childhood death into a chronic condition. With increased lifespan, comorbidities associated with the disease have become more common, among them glucose dysregulation (GD) which devel-ops insidiously, aggravating prognosis and patients’ quality of life. Objectives: The objectives of this study were to retrospectively review the extent to which β-TM patients, having combined impaired fasting glucose (IFG) and impaired glucose tolerance test (IGT) on oral glucose tolerance test (OGTT), progressed to diabetes and to analyze the potential determinants inducing this progression, or regression to normal glucose tolerance test (NGT). Research design and method: Data of 58 β-TM patients, followed for a mean duration of 7.7 years (range: 1-20 years) with annual or biennial OGTT, were retrieved. Insulin release and insulin sensitivity (IS) were also analyzed. Results: During the follow-up, FPG and 2-h PG levels after OGTT reverted to NGT in 13 patients (22.4%), deteriorated in 13 patients (22.4%) who developed diabetes mellitus, and did not change in the remaining 32 patients (55.2%). A significant correlation was observed between FPG and ALT level (r: 0.3158; P:0.01) and an inverse correlation was found between chronological age and serum ferritin (SF) level (r:-0.321; P:0.014). Finally, SF and ALT, both at the baseline and at the time of last observation, were independent predictors of evolution to diabetes mellitus. Conclusion: The combination IFG/IGT in β-TM patients with severe iron overload constitutes a high-risk state for developing diabetes. (www.actabiomedica.it).
KW - combination IFG/IGT
KW - follow-up
KW - iron overload
KW - liver enzymes
KW - prediabetes
KW - β-thalassemia major
UR - http://www.scopus.com/inward/record.url?scp=85133293708&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133293708&partnerID=8YFLogxK
U2 - 10.23750/abm.v93i3.12825
DO - 10.23750/abm.v93i3.12825
M3 - Article
C2 - 35775758
AN - SCOPUS:85133293708
SN - 0392-4203
VL - 93
JO - Acta Biomedica
JF - Acta Biomedica
IS - 3
M1 - e2022242
ER -